Rujukan Perencat pam proton

  1. 1 2 3 "[99] Comparative effectiveness of proton pump inhibitors". Therapeutics Letter. 28 June 2016. ISSN 2369-8691. Dicapai pada 14 July 2016.
  2. 1 2 3 "Review article: the clinical pharmacology of proton pump inhibitors". Alimentary Pharmacology & Therapeutics. 23 (Suppl 2): 2–8. June 2006. doi:10.1111/j.1365-2036.2006.02943.x. PMID 16700898.
  3. ↑ "Current Trends in the Management of Gastroesophageal Reflux Disease". Gut Liver. 12 (1): 7–16. January 2018. doi:10.5009/gnl16615. PMC 5753679. PMID 28427116.
  4. 1 2 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. 1 2 World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  6. ↑ "An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia". Osteopathic Family Physician. 5 (2): 79–85. March–April 2013. doi:10.1016/j.osfp.2012.10.005.
  7. ↑ "Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials". Clinical Gastroenterology and Hepatology. 5 (2): 178–85, quiz 140. February 2007. doi:10.1016/j.cgh.2006.09.012. PMID 17174612. Unknown parameter |displayauthors= ignored (bantuan)
  8. ↑ "Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis". JAMA Internal Medicine. 174 (11): 1755–62. November 2014. doi:10.1001/jamainternmed.2014.4056. PMC 4415726. PMID 25201154.
  9. ↑ "Optimum duration of regimens for Helicobacter pylori eradication". The Cochrane Database of Systematic Reviews. 12 (12): CD008337. December 2013. doi:10.1002/14651858.CD008337.pub2. PMID 24338763. Unknown parameter |displayauthors= ignored (bantuan)
  10. ↑ "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease". The Cochrane Database of Systematic Reviews. 5 (5): CD002095. May 2013. doi:10.1002/14651858.CD002095.pub5. PMC 7066537. PMID 23728637.
  11. ↑ "Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials". The American Journal of Gastroenterology. 101 (11): 2646–54. November 2006. PMID 17037995. Unknown parameter |displayauthors= ignored (bantuan)
  12. ↑ "Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux". BMJ. 332 (7532): 11–7. January 2006. doi:10.1136/bmj.38677.559005.55. PMC 1325125. PMID 16330475.
  13. 1 2 "Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis". Gut. 63 (8): 1229–37. August 2014. doi:10.1136/gutjnl-2013-305997. PMC 4199831. PMID 24221456.
  14. ↑ "Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis". Clinical Gastroenterology and Hepatology. 14 (1): 13–22.e1. January 2016. doi:10.1016/j.cgh.2015.07.041. PMID 26247167.
  15. ↑ "Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis". Critical Care Medicine. 41 (3): 693–705. March 2013. doi:10.1097/CCM.0b013e3182758734. PMID 23318494.
  16. ↑ "Zollinger-Ellison syndrome: classical considerations and current controversies". The Oncologist. 19 (1): 44–50. January 2014. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.
  17. ↑ "Five Things Physicians and Patients Should Question". American Gastroenterological Association. 24 February 2015.
  18. ↑ "American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease". Gastroenterology. 135 (4): 1383–1391, 1391.e1-5. October 2008. doi:10.1053/j.gastro.2008.08.045. PMID 18789939. Unknown parameter |displayauthors= ignored (bantuan)
  19. 1 2 3 "Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study". BMJ. Washington University School of Medicine. 365: l1580. May 2019. doi:10.1136/bmj.l1580. PMC 6538974. PMID 31147311. Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
  20. 1 2 "FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors". U.S. Food and Drug Administration (FDA). 23 March 2011. Dicapai pada 23 August 2015.
  21. 1 2 "Low magnesium levels can be associated with long-term use of PPIs". U.S. Food and Drug Administration (FDA). 17 November 2009. Dicapai pada 23 February 2020.
  22. ↑ "Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence". Alimentary Pharmacology & Therapeutics. 23 (6): 727–33. March 2006. doi:10.1111/j.1365-2036.2006.02825.x. PMID 16556174.
  23. ↑ "PPIs should not be prescribed for throat symptoms". NIHR Evidence (dalam bahasa Inggeris). 2022-01-13. Dicapai pada 2022-07-06.
  24. ↑ Wilson, Janet A.; Stocken, Deborah D.; Watson, Gillian C.; Fouweather, Tony; McGlashan, Julian; MacKenzie, Kenneth; Carding, Paul; Karagama, Yakubu; Harries, Meredydd (2021-01-22). "Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT". Health Technology Assessment (dalam bahasa Inggeris). 25 (3): 1–118. doi:10.3310/hta25030. ISSN 2046-4924. PMC 7869007. PMID 33492208.
  25. 1 2 3 "Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline". Canadian Family Physician. 63 (5): 354–364. May 2017. PMC 5429051. PMID 28500192. Unknown parameter |displayauthors= ignored (bantuan)
  26. ↑ "Canadian Cardiovascular Society and Choosing Wisely Canada: The Road to Creating a List of Five Things Physicians and Patients Should Question". Canadian Journal of Cardiology. 30 (8): 949–955. August 2014. doi:10.1016/j.cjca.2014.06.010. ISSN 0828-282X.
  27. ↑ "[111] Deprescribing Proton Pump Inhibitors". Therapeutics Initiative. 26 June 2018. Dicapai pada 27 June 2018.
  28. ↑ "Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?". European Journal of Clinical Pharmacology. 62 (6): 473–9. June 2006. doi:10.1007/s00228-006-0131-1. PMID 16758264.
  29. ↑ "Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services". Drugs - Real World Outcomes. 6 (3): 105–113. September 2019. doi:10.1007/s40801-019-0157-1. PMC 6702506. PMID 31264165. Unknown parameter |displayauthors= ignored (bantuan)
  30. 1 2 3 4 5 6 7 "Proton pump inhibitor therapy and potential long-term harm". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (1): 3–8. February 2014. doi:10.1097/MED.0000000000000031. PMID 24310148.
  31. 1 2 3 4 5 "The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association". Gastroenterology. 152 (4): 706–715. March 2017. doi:10.1053/j.gastro.2017.01.031. PMID 28257716. Conclusions:Baseline differences between PPI users and non-users make it challenging to study potential PPI adverse effects retrospectively. Despite a large number of studies, the overall quality of evidence for PPI adverse effects is low to very low. When PPIs are appropriately prescribed, their benefits are likely to outweigh their risks. When PPIs are inappropriately prescribed, modest risks become important because there is no potential benefit. There is currently insufficient evidence to recommend specific strategies for mitigating PPI adverse effects.
  32. 1 2 3 4 "Complications of Proton Pump Inhibitor Therapy". Gastroenterology. 153 (1): 35–48. July 2017. doi:10.1053/j.gastro.2017.04.047. PMID 28528705. In turn, this has caused unnecessary concern among patients and prescribers. The benefits of PPI therapy for appropriate indications need to be considered, along with the likelihood of the proposed risks. Patients with a proven indication for a PPI should continue to receive it in the lowest effective dose. PPI dose escalation and continued chronic therapy in those unresponsive to initial empiric therapy is discouraged.
  33. ↑ "Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials". BMC Medicine. 19 (1): 316. December 2021. doi:10.1186/s12916-021-02180-5. PMC 8641218 Check |pmc= value (bantuan). PMID 34856983 Check |pmid= value (bantuan). Unknown parameter |displayauthors= ignored (bantuan)
  34. 1 2 "Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium". Current Gastroenterology Reports. 12 (6): 448–57. December 2010. doi:10.1007/s11894-010-0141-0. PMC 2974811. PMID 20882439.
  35. ↑ "The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis". PLOS ONE. 9 (11): e112558. 2014. Bibcode:2014PLoSO...9k2558P. doi:10.1371/journal.pone.0112558. PMC 4230950. PMID 25394217.
  36. ↑ Malchodi, Laura; Wagner, Kari; Susi, Apryl; Gorman, Gregory; Hisle-Gorman, Elizabeth (July 2019). "Early Acid Suppression Therapy Exposure and Fracture in Young Children". Pediatrics. 144 (1): e20182625. doi:10.1542/peds.2018-2625. ISSN 1098-4275. PMID 31175146.
  37. ↑ Nehra, Avinash K.; Alexander, Jeffrey A.; Loftus, Conor G.; Nehra, Vandana (2018). "Proton Pump Inhibitors: Review of Emerging Concerns". Mayo Clinic Proceedings (dalam bahasa Inggeris). 93 (2): 240–246. doi:10.1016/j.mayocp.2017.10.022. PMID 29406201.
  38. ↑ "What are the effects of proton pump inhibitors on the small intestine?". World Journal of Gastroenterology. 21 (22): 6817–9. June 2015. doi:10.3748/wjg.v21.i22.6817. PMC 4462721. PMID 26078557. Generally, proton-pump inhibitors (PPIs) have great benefit for patients with acid related disease with less frequently occurring side effects. According to a recent report, PPIs provoke dysbiosis of the small intestinal bacterial flora, exacerbating nonsteroidal anti-inflammatory drug-induced small intestinal injury. Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth (SIBO) compared to patients who lack the aforementioned conditions. Furthermore, there is insufficient evidence that these conditions induce Clostridium difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO.
  39. ↑ "Small intestinal fungal overgrowth". Current Gastroenterology Reports. 17 (4): 16. April 2015. doi:10.1007/s11894-015-0436-2. PMID 25786900. Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26% (24/94) and 25.3% (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms.
  40. ↑ "High prevalence of reflux esophagitis among upper endoscopies in Chinese patients with chronic liver diseases". BMC Gastroenterology. 10 (1): 54. June 2010. doi:10.1186/1471-230X-10-54. PMC 2889852. PMID 20525368.
  41. ↑ "Esophageal motility in cirrhotics with and without esophageal varices". Scandinavian Journal of Gastroenterology. 24 (3): 334–8. April 1989. doi:10.3109/00365528909093056. PMID 2734592.
  42. ↑ "Esophageal function after injection sclerotherapy: pathogenesis of esophageal stricture". American Journal of Surgery. 147 (1): 85–8. January 1984. doi:10.1016/0002-9610(84)90039-4. PMID 6606991.
  43. ↑ "Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding". Journal of Gastroenterology and Hepatology. 28 (4): 684–9. April 2013. doi:10.1111/jgh.12107. PMID 23278466.
  44. ↑ "Deleterious effect of proton pump inhibitors on the disease course of cirrhosis". European Journal of Gastroenterology & Hepatology (dalam bahasa Inggeris). 32 (2): 257–264. February 2020. doi:10.1097/MEG.0000000000001499. PMID 31464790.
  45. ↑ "Proton pump inhibitors alter the composition of the gut microbiota". Gut. 65 (5): 749–756. May 2016. doi:10.1136/gutjnl-2015-310861. PMC 4853574. PMID 26719299. Unknown parameter |displayauthors= ignored (bantuan)
  46. 1 2 "Proton pump inhibitors and helicobacter pylori-associated pathogenesis". Asian Pacific Journal of Cancer Prevention. 16 (4): 1315–1319. 2015. doi:10.7314/APJCP.2015.16.4.1315. PMID 25743791.
  47. ↑ "Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study". Gut. 67 (1): 28–35. January 2018. doi:10.1136/gutjnl-2017-314605. PMID 29089382.
  48. ↑ "Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication". Journal of the Canadian Association of Gastroenterology. 1 (4): 155–158. December 2018. doi:10.1093/jcag/gwy040. PMC 6542241. PMID 31294357.
  49. ↑ "Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence". Therapeutic Advances in Gastroenterology. 12: 1756284819834511. January 2019. doi:10.1177/1756284819834511. PMC 6415482. PMID 30886648.
  50. ↑ "Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group". Journal of Crohn's & Colitis. 6 (9): 932–45. October 2012. doi:10.1016/j.crohns.2012.05.014. PMID 22704658. Unknown parameter |displayauthors= ignored (bantuan)
  51. 1 2 "Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy". European Heart Journal. 34 (23): 1708–13, 1713a–1713b. June 2013. doi:10.1093/eurheartj/eht042. PMID 23425521. Unknown parameter |displayauthors= ignored (bantuan)
  52. ↑ "Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review". Circulation: Cardiovascular Quality and Outcomes. 8 (1): 47–55. January 2015. doi:10.1161/CIRCOUTCOMES.114.001177. PMC 6143138. PMID 25587094. Unknown parameter |displayauthors= ignored (bantuan)
  53. ↑ "Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis". Drug Safety. 34 (1): 47–57. January 2011. doi:10.2165/11584750-000000000-00000. PMID 21047145.
  54. ↑ "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–7. April 2013. doi:10.1136/heartjnl-2012-302371. PMID 22851683.
  55. ↑ "Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis". Open Heart. 2 (1): e000248. 2015. doi:10.1136/openhrt-2015-000248. PMC 4488889. PMID 26196021. Unknown parameter |displayauthors= ignored (bantuan)
  56. ↑ "Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials". BMC Medicine. Springer Science and Business Media LLC. 19 (1): 316. December 2021. doi:10.1186/s12916-021-02180-5. PMC 8641218 Check |pmc= value (bantuan). PMID 34856983 Check |pmid= value (bantuan). Unknown parameter |displayauthors= ignored (bantuan)
  57. ↑ "Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?". Seminars in Nephrology. 34 (2): 97–105. March 2014. doi:10.1016/j.semnephrol.2014.02.003. PMID 24780466. It also seems to be the pathophysiological link between the use of proton pump inhibitors and increased cardiovascular event rate because these medications bind and inhibit DDAH, the enzyme that degrades ADMA, which results in higher ADMA levels and a decrease in bioavailable NO.
  58. ↑ Zhang, M. L.; Fan, Y. X.; Meng, R.; Cai, W. K.; Yin, S. J.; Zhou, T.; Huang, Y. H.; Wang, P.; Jiang, F. F. (2022). "Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies". American Journal of Clinical Oncology. 45 (11): 475–485. doi:10.1097/COC.0000000000000949. PMID 36255347 Check |pmid= value (bantuan).
  59. ↑ "Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis". PLOS ONE. 10 (6): e0128004. 2015. Bibcode:2015PLoSO..1028004L. doi:10.1371/journal.pone.0128004. PMC 4456166. PMID 26042842.
  60. ↑ "Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis". CMAJ. 183 (3): 310–9. February 2011. doi:10.1503/cmaj.092129. PMC 3042441. PMID 21173070.
  61. ↑ "Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies". Clinical Epidemiology and Global Health. 7: 46–52. 2019. doi:10.1016/j.cegh.2017.12.008.
  62. ↑ "Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease". JAMA Internal Medicine. American Medical Association (AMA). 176 (2): 238–46. February 2016. doi:10.1001/jamainternmed.2015.7193. PMC 4772730. PMID 26752337.
  63. ↑ "Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury". Kidney International. Elsevier BV. 91 (6): 1482–1494. June 2017. doi:10.1016/j.kint.2016.12.021. PMID 28237709.
  64. ↑ "Proton Pump Inhibitors and CKD". Journal of the American Society of Nephrology. American Society of Nephrology (ASN). 27 (10): 2926–2928. October 2016. doi:10.1681/asn.2016020192. PMC 5042680. PMID 27080978.
  65. ↑ "Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD". Journal of the American Society of Nephrology. American Society of Nephrology (ASN). 27 (10): 3153–3163. October 2016. doi:10.1681/asn.2015121377. PMC 5042677. PMID 27080976.
  66. ↑ Salman Hussain, Ambrish Singh et al. No association between proton pump inhibitors use and risk of dementia: Evidence from a meta-analysis. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.14789
  67. ↑ "Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors". Current Treatment Options in Gastroenterology. 15 (1): 1–9. March 2017. doi:10.1007/s11938-017-0115-5. PMID 28130652. The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general.
  68. ↑ Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. J Evid Based Med. 2021;14(4):278-280. doi: 10.1111/jebm.12456. Epub 2021 Oct 13. PMID: 34643998.
  69. ↑ "Therapy: Risks associated with chronic PPI use - signal or noise?". Nature Reviews. Gastroenterology & Hepatology. 13 (5): 253–4. May 2016. doi:10.1038/nrgastro.2016.44. PMID 27006255.
  70. ↑ Sakai H, Fujii T, Takeguchi N (2016). "Chapter 13. Proton-Potassium (H+/K+) ATPases: Properties and Roles in Health and Diseases". Dalam Astrid S, Helmut S, Roland SK (penyunting). The Alkali Metal Ions: Their Role in Life. Metal Ions in Life Sciences. 16. Springer. m/s. 459–483. doi:10.1007/978-3-319-21756-7_13. PMID 26860309.
  71. ↑ Fellenius, Erik; Berglindh, Thomas; Sachs, George; Olbe, Lars; Elander, Berit; Sjöstrand, Sven-Erik; Wallmark, Björn (March 1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase". Nature. 290 (5802): 159–161. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. ISSN 0028-0836. PMID 6259537.
  72. ↑ Shin, Jai Moo; Sachs, George (November 2002). "Restoration of acid secretion following treatment with proton pump inhibitors". Gastroenterology. 123 (5): 1588–1597. doi:10.1053/gast.2002.36593. ISSN 0016-5085. PMID 12404233.
  73. ↑ "Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness". World J Gastroenterol. 25 (34): 5097–5104. September 2019. doi:10.3748/wjg.v25.i34.5097. PMC 6747288. PMID 31558859.
  74. ↑ "Proton pump inhibitors: better acid suppression when taken before a meal than without a meal". Alimentary Pharmacology & Therapeutics. 14 (10): 1267–72. October 2000. doi:10.1046/j.1365-2036.2000.00829.x. PMID 11012470.
  75. ↑ AstraZeneca Pty Ltd. Nexium (Australian approved prescribing information). North Ryde: AstraZeneca; 2005.
  76. ↑ Wyeth Australia Pty Ltd. Zoton (Australian approved prescribing information). Baulkham Hills: Wyeth; 2004.
  77. 1 2 Shin, Jai Moo; Sachs, George (December 2008). "Pharmacology of proton pump inhibitors". Current Gastroenterology Reports (dalam bahasa Inggeris). 10 (6): 528–534. doi:10.1007/s11894-008-0098-4. ISSN 1522-8037. PMC 2855237. PMID 19006606.
  78. ↑ "The gastric HK-ATPase: structure, function, and inhibition". Pflügers Archiv. 457 (3): 609–22. January 2009. doi:10.1007/s00424-008-0495-4. PMC 3079481. PMID 18536934.
  79. ↑ "Two of a kind". Chemistry in Britain. 38 (5): 42–5. 2002.
  80. 1 2 "Omeprazole and Esomeprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  81. 1 2 "Lansoprazole, Dexlansoprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  82. ↑ "Pantoprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  83. ↑ "Rabeprazole". Clinical and Research Information on Drug-induced Liver Injury. National Institutes of Health (NIH). Retrieved May 8, 2018.
  84. 1 2 Dean L (1 October 2010). Comparing Proton Pump Inhibitors. PubMed Health. National Center for Biotechnology Information (US). Dicapai pada 16 July 2016.
  85. ↑ "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". Journal of Gastroenterology and Hepatology. 25 (10): 1618–25. October 2010. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169. Unknown parameter |displayauthors= ignored (bantuan)
  86. ↑ "Proton Pump Inhibitors in Primary Care" (PDF). Province of British Columbia. January 2015.
  87. ↑ "Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching". Gut. 70 (1): 76–84. January 2021. doi:10.1136/gutjnl-2020-322248. PMID 32732368. Unknown parameter |displayauthors= ignored (bantuan)

Rujukan

WikiPedia: Perencat pam proton http://www.medicinenet.com/proton-pump_inhibitors/... http://snomed.info/id/372525000 http://www.choosingwisely.org/doctor-patient-lists... http://dx.doi.org/10.1038/290159a0 https://www2.gov.bc.ca/assets/gov/health/practitio... https://www.ti.ubc.ca/2016/06/28/99-comparative-ef... https://www.ti.ubc.ca/2018/06/26/111-deprescribing... https://www.drugs.com/drug-class/proton-pump-inhib... https://ui.adsabs.harvard.edu/abs/2014PLoSO...9k25... https://ui.adsabs.harvard.edu/abs/2015PLoSO..10280...